Fertility with PCOS — Cycle Irregularity & Conception Tips

Understanding PCOS and Its Impact on Fertility

Polycystic ovary syndrome (PCOS) affects an estimated 8% to 13% of women of reproductive age worldwide, making it the most common cause of female infertility. PCOS is characterized by the Rotterdam criteria: at least two of three features must be present — oligo-ovulation or anovulation (irregular or absent ovulation), clinical or biochemical hyperandrogenism (elevated androgens such as testosterone), and polycystic ovarian morphology on ultrasound (12 or more follicles per ovary, each 2 to 9 mm in diameter). Up to 70% of women with PCOS experience irregular or absent ovulation, which directly impairs their ability to conceive naturally. Without ovulation, there is no egg released and no conception is possible. The condition also increases the risk of gestational diabetes, preeclampsia, and miscarriage, making preconception counseling and early prenatal care especially important for women with PCOS.

Cycle Irregularity and Anovulation

Cycle irregularity is the hallmark of PCOS and the primary driver of infertility in these women. Normal cycles range from 21 to 35 days, but women with PCOS often experience cycles longer than 35 days, and some go months without a period (oligomenorrhea or amenorrhea). The underlying mechanism involves an imbalance between follicle-stimulating hormone (FSH) and luteinizing hormone (LH) — LH is typically elevated while FSH is low or normal, which prevents the dominant follicle from maturing and ovulating. Chronic anovulation means no corpus luteum forms, no progesterone is produced, and the uterine lining continues to build under estrogen influence without being shed, increasing the risk of endometrial hyperplasia and, over the long term, endometrial cancer. Tracking cycle length — even irregular ones — provides data that helps clinicians assess ovulatory function and guide treatment.

Weight and Insulin Resistance

Insulin resistance is present in approximately 50% to 70% of women with PCOS, regardless of body weight, though it is more pronounced in women who are overweight or obese. Insulin resistance leads to compensatory hyperinsulinemia, which stimulates the ovarian theca cells to produce excess androgens and suppresses the liver from producing sex hormone-binding globulin (SHBG), thereby increasing free testosterone levels. This hormonal cascade further disrupts ovulation and makes the cycle even more irregular. The World Health Organization (WHO) and the International Evidence-based Guideline for the Assessment and Management of PCOS (2023) both emphasize weight management and insulin-sensitizing therapies as first-line treatments for fertility in women with PCOS who are overweight. Losing just 5% to 10% of body weight has been shown to restore ovulation in approximately 50% of anovulatory women with PCOS who are overweight.

Lifestyle Interventions

Lifestyle modification is the first-line treatment for fertility in women with PCOS, particularly for those who are overweight. A moderate caloric deficit of 500 to 750 calories per day, combined with at least 150 minutes of moderate-intensity exercise per week, is the standard recommendation. A study published in the New England Journal of Medicine demonstrated that a weight loss of 5% to 10% restored spontaneous ovulation in over 50% of women with PCOS who were overweight, often within 3 to 6 months. Diet quality matters as well — low-glycemic index diets and Mediterranean-style eating patterns have been shown to improve insulin sensitivity and androgen levels more effectively than standard advice. Regular physical activity reduces insulin resistance independently of weight loss and improves overall metabolic health. Many women with PCOS find that combining lifestyle changes with metformin therapy produces even better results than either approach alone.

Medical Ovulation Induction Options

For women with PCOS who do not ovulate with lifestyle changes alone, ovulation induction medications are the standard next step. Letrozole (Femara) is now the first-line medication recommended by the Endocrine Society and ASRM, based on the landmark PPCOS II trial which showed letrozole achieved higher ovulation and live birth rates than clomiphene citrate (Clomid) in women with PCOS. Letrozole works by temporarily blocking estrogen synthesis, which triggers a compensatory rise in FSH that stimulates follicle growth. Clomiphene citrate is an older option that acts as a selective estrogen receptor modulator (SERM) and remains widely used. Gonadotropin injections are used for women who do not respond to oral medications, though they carry a higher risk of multiple gestation and ovarian hyperstimulation syndrome (OHSS). Metformin, an insulin-sensitizing drug, is often used as an adjunct to letrozole or clomiphene and is particularly beneficial for women with insulin resistance.